Nexalin Technology (NASDAQ:NXL – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.28) EPS for the quarter, Zacks reports. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%.
Nexalin Technology Stock Up 10.3 %
NASDAQ:NXL traded up $0.20 on Friday, reaching $2.15. 115,733 shares of the company’s stock traded hands, compared to its average volume of 1,354,446. The stock has a 50-day simple moving average of $2.87 and a 200-day simple moving average of $2.47. Nexalin Technology has a 12 month low of $0.35 and a 12 month high of $4.49. The firm has a market cap of $28.60 million, a PE ratio of -3.36 and a beta of 4.33.
Wall Street Analyst Weigh In
Separately, Maxim Group reissued a “hold” rating on shares of Nexalin Technology in a report on Thursday, December 5th.
Nexalin Technology Company Profile
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
Featured Articles
- Five stocks we like better than Nexalin Technology
- Do ETFs Pay Dividends? What You Need to Know
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What Investors Need to Know to Beat the Market
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
